Improvement of health status evaluated by Arthritis Impact Measurement Scale 2 (AIMS-2) and Short Form-36 (SF-36) in patients with rheumatoid arthritis treated with tocilizumab
Modern Rheumatology, 06/11/2012
Fusama M et al. - The time-course diversity in improvement of health status should be considered to provide proper healthcare when treated with tocilizumab.Methods
- Thirty-nine patients were treated with 8 mg/kg tocilizumab every 4 weeks for 24 weeks.
- Disease activity was assessed by Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI).
- Improvement of health status was assessed by Arthritis Impact Measurement Scale 2 (AIMS-2) and Short Form-36 (SF-36).
- Tocilizumab improved CDAI and SDAI significantly at week 4 compared with at baseline.
- In the components of AIMS-2, “physical score”, “symptom” and “affect” improved significantly at week 4 compared with at baseline, while “social interaction” did not improve significantly during 24 weeks of tocilizumab therapy.
- Similarly in SF-36, “bodily pain”, “general health”, “vitality” and “mental health” improved significantly at week 4.
- The most correlative component of AIMS-2 with CDAI was “symptom”, while “social interaction” did not correlate with CDAI during tocilizumab treatment.